Clinical Trials Logo

Refractory Multiple Myeloma clinical trials

View clinical trials related to Refractory Multiple Myeloma.

Filter by:

NCT ID: NCT04439331 Active, not recruiting - Clinical trials for Hematopoietic and Lymphoid Cell Neoplasm

Testing VS-6063 (Defactinib) as a Potential Targeted Treatment in Cancers With NF2 Genetic Changes (MATCH-Subprotocol U)

Start date: August 12, 2015
Phase: Phase 2
Study type: Interventional

This phase II MATCH treatment trial identifies the effects of VS-6063 (defactinib) in patients whose cancer has a genetic change called NF2 mutation. Defactinib may block a protein called FAK, which may be needed for cancer cell growth when NF2 mutations are present. Researchers hope to learn if defactinib will shrink this type of cancer or stop its growth.

NCT ID: NCT04439318 Active, not recruiting - Clinical trials for Hematopoietic and Lymphoid Cell Neoplasm

Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1)

Start date: February 25, 2016
Phase: Phase 2
Study type: Interventional

This phase II MATCH treatment trial identifies the effects of trametinib in patients whose cancer has a has a genetic change called NF1 mutation. Trametinib blocks proteins called MEK1 and MEK2, which may be needed for cancer cell growth when an NF1 mutation is present. Researchers hope to learn if trametinib will shrink this type of cancer or stop its growth.

NCT ID: NCT04439292 Active, not recruiting - Clinical trials for Hematopoietic and Lymphoid Cell Neoplasm

Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)

Start date: August 12, 2015
Phase: Phase 2
Study type: Interventional

This phase II MATCH treatment trial identifies the effects of trametinib and dabrafenib in patients whose cancer has genetic changes called BRAF V600 mutations. Dabrafenib may stop the growth of cancer by blocking BRAF proteins which may be needed for cell growth. Trametinib may stop the growth of cancer cells by blocking MEK proteins which, in addition to BRAF proteins, may also be needed for cell growth. Researchers hope to learn if giving trametinib with dabrafenib will shrink this type of cancer or stop its growth.

NCT ID: NCT04439279 Active, not recruiting - Clinical trials for Hematopoietic and Lymphoid Cell Neoplasm

Testing Trametinib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol R)

Start date: August 12, 2015
Phase: Phase 2
Study type: Interventional

This phase II MATCH treatment trial identifies the effects of trametinib in patients with cancer having genetic changes called BRAF mutations and fusions. Trametinib may block proteins called MEK1 and MEK2, which may be needed for growth of cancer cells that express BRAF mutations. Researchers hope to learn if giving trametinib will shrink this type of cancer or stop its growth.

NCT ID: NCT04439266 Active, not recruiting - Clinical trials for Hematopoietic and Lymphoid Cell Neoplasm

Testing Crizotinib as a Potential Targeted Treatment in Cancers With ALK Genetic Changes (MATCH-Subprotocol F)

Start date: August 12, 2015
Phase: Phase 2
Study type: Interventional

This phase II MATCH treatment trial identifies the effects of crizotinib in patients whose cancer has a genetic change called ALK rearrangement. Crizotinib may stop the growth of cancer cells by blocking the ALK protein which may be needed for cell growth. Researchers hope to learn if crizotinib will shrink this type of cancer or stop its growth.

NCT ID: NCT04439253 Active, not recruiting - Clinical trials for Hematopoietic and Lymphoid Cell Neoplasm

Testing Crizotinib as a Potential Targeted Treatment in Cancers With ROS1 Genetic Changes (MATCH-Subprotocol G)

Start date: August 12, 2015
Phase: Phase 2
Study type: Interventional

This phase II MATCH treatment trial identifies the effects of crizotinib in patients whose cancer has a genetic change called ROS1 translocation. Crizotinib may block a protein called ROS1, which may be needed for cancer cell growth. Researchers hope to learn if crizotinib will shrink this type of cancer or stop its growth.

NCT ID: NCT04439227 Active, not recruiting - Clinical trials for Hematopoietic and Lymphoid Cell Neoplasm

Testing AZD1775 as a Potential Targeted Treatment in Cancers With BRCA Genetic Changes (MATCH-Subprotocol Z1I)

Start date: March 13, 2017
Phase: Phase 2
Study type: Interventional

This phase II MATCH treatment trial identifiesay block the protein tyrosine kinase WEE1 the effects of AZD1775 in patients whose cancer has a genetic change called BRCA mutation. AZD1775 may block a protein called WEE1, which may be needed for growth of cancer cells that express BRCA mutations. Researchers hope to learn if AZD1775 will shrink this type of cancer or stop its growth.

NCT ID: NCT04439188 Active, not recruiting - Clinical trials for Hematopoietic and Lymphoid Cell Neoplasm

Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Loss of Expression (MATCH-Subprotocol P)

Start date: February 25, 2016
Phase: Phase 2
Study type: Interventional

This phase II MATCH treatment trial identifies the effects of GSK2636771 in patients whose cancer has a complete loss of PTEN expression. GSK2636771 may block a protein called PI3K-beta, which may be needed for growth of cancer cells with complete loss of PTEN expression. Researchers hope to learn if GSK2636771 will shrink this type of cancer or stop its growth.

NCT ID: NCT04439175 Active, not recruiting - Clinical trials for Hematopoietic and Lymphoid Cell Neoplasm

Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I)

Start date: February 25, 2016
Phase: Phase 2
Study type: Interventional

This phase II MATCH treatment trial identifies the effects of GDC-0032 (taselisib) in patients whose cancer has a genetic change called PIK3CA mutation. Taselisib may stop the growth of cancer cells by blocking PIK3CA, a protein that may be needed for cell growth. Researchers hope to learn if taselisib will shrink this type of cancer or stop its growth.

NCT ID: NCT04439149 Active, not recruiting - Clinical trials for Hematopoietic and Lymphoid Cell Neoplasm

Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N)

Start date: February 25, 2016
Phase: Phase 2
Study type: Interventional

This phase II MATCH treatment trial identifies the effects of GSK2636771 in patients whose cancer has a genetic change called PTEN mutation or deletion. GSK2636771 may block a protein called PI3K-beta, which may be needed for growth of cancer cells that express PTEN mutations. Researchers hope to learn if GSK2636771 will shrink this type of cancer or stop its growth.